Given that in numerous tissues and pathological states PPAR gamma activation induces repression of the Wnt/beta-catenin pathway (Moldes et al., 2003; Sharma et al., 2004; Liu et al., 2006), the rationale for using PPAR gamma in AD would seem to merit discussion. Here, PPARG is linked to Alzheimer disease.